Novartis AG (NVS)
110.53
+1.18
(+1.08%)
USD |
NYSE |
Nov 04, 16:00
110.15
-0.38
(-0.34%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 220.98B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 20.39% |
| Valuation | |
| PE Ratio | 12.96 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.539 |
| Price to Book Value | 5.101 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 3.777 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.6999 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 25.84% |
Profile
| Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue. |
| URL | https://www.novartis.com |
| Investor Relations URL | https://www.novartis.com/investors |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Jan. 31, 2025 |
| Last Earnings Release | Oct. 29, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 07, 2024 |
Ratings
Profile
| Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue. |
| URL | https://www.novartis.com |
| Investor Relations URL | https://www.novartis.com/investors |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Jan. 31, 2025 |
| Last Earnings Release | Oct. 29, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 07, 2024 |